17,95 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
  • Broschiertes Buch

Seminar paper from the year 2019 in the subject Medicine - Pharmacology, , language: English, abstract: The objective of this text is to study the relationship between the governance structure and the input intensity of R & D investment of pharmaceutical enterprises, and to check the lag effect of R & D input on the performance. The data of the balanced panel of 133 medical-listed enterprises from 2009 to 2016 were taking as samples, the regression analysis was performed by using the STATA13.0 software. In the aspect of the ownership structure, the state-owned control has a negative effect on…mehr

Produktbeschreibung
Seminar paper from the year 2019 in the subject Medicine - Pharmacology, , language: English, abstract: The objective of this text is to study the relationship between the governance structure and the input intensity of R & D investment of pharmaceutical enterprises, and to check the lag effect of R & D input on the performance. The data of the balanced panel of 133 medical-listed enterprises from 2009 to 2016 were taking as samples, the regression analysis was performed by using the STATA13.0 software. In the aspect of the ownership structure, the state-owned control has a negative effect on the R & D investment intensity, and the equity concentration degree and the equity balance degree are positive. In terms of the governance of the board of directors, the proportion of the two-level and independent directors is positively affecting the strength of R & D and the scale of the board of directors has a negative effect. In that case of executive motivation, the share power incentive and salary incentive do not play the desired positive role. The lag effect of R & D investment on enterprise performance has verified. With the passage of time, the relationship between R & D investment and enterprise performance has gradually changed from significant negative to significant positive. Based on the research results, some suggestions are put forward to provide empirical evidence for optimizing the internal governance structure of pharmaceutical enterprises and improving the efficiency of R & D.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.